Novartis announces USD 5 billion bond issue
(Thomson Reuters ONE) -
Novartis International AG / Novartis announces USD 5 billion bond issue processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Basel, March 10, 2010 - Novartis announced today a USD 5 billion bond market
transaction consisting of three tranches:
* USD 2 billion 1.900% Notes due April 24, 2013
* USD 2 billion 2.900% Notes due April 24, 2015
* USD 1 billion 4.400% Notes due April 24, 2020
These notes are registered with the U.S. Securities and Exchange Commission
under an automatic shelf registration statement filed by Novartis in 2008. All
three tranches are issued by Novartis Capital Corporation, a U.S. subsidiary,
and are unconditionally guaranteed by Novartis AG, which is incorporated in
Switzerland and is the ultimate parent company of Novartis Capital Corporation.
Proceeds will be used for intercompany refinancing purposes in connection with
the pending Alcon acquisition, as well as for general corporate purposes.
Novartis AG is rated Aa2 (negative outlook) by Moody's and AA- (stable outlook)
by Standard & Poor's. Goldman Sachs & Co., J.P. Morgan, Barclays Capital, BofA
Merrill Lynch, Citi and Morgan Stanley were joint book-runners.
A copy of the prospectus relating to this offering can be obtained on the EDGAR
website operated by the SEC or by contacting the underwriters through Goldman
Sachs & Co., Prospectus Department, 85 Broad Street, New York, New York, 10004,
Tel: +1-866-471-2526, Fax: +1-212-902-9316, or by e-mailing
prospectus-ny(at)ny.email.gs.com
J.P. Morgan Securities Inc., 270 Park Avenue, New York, New York 10017, Tel:
+1-212-834-4533.
This press release shall not constitute an offer to sell or a solicitation of an
offer to buy, nor shall there be any sale of the notes in any state or
jurisdiction in which such offer, solicitation or sale is unlawful prior to
registration or qualification under the securities laws of any such state or
jurisdiction.
Disclaimer
This release contains certain forward-looking statements relating to the
Novartis Group's business, which can be identified by terminology such as
"will," or similar expressions, or by express or implied discussions regarding
the potential value of the notes described in this release, the Novartis Group's
ability to repay all or any part of the notes, potential future sales or
earnings of the Novartis Group or any of its divisions or business units; or
regarding the potential acquisition of, and merger with, Alcon; or by
discussions of strategy, plans, expectations or intentions. You should not place
undue reliance on these statements. Such forward-looking statements reflect the
current views of Novartis Group management regarding future events, and involve
known and unknown risks, uncertainties and other factors that may cause actual
results to be materially different from any future results, performance or
achievements expressed or implied by such statements. There can be no guarantee
that the notes will have any particular value or can be sold or re-sold for any
particular value. Nor can there be any guarantee that the Novartis Group will
be able to repay all or any part of the notes, or that the Novartis Group, or
any of its divisions or business units, will achieve any particular financial
results. There can be no guarantee that the proposed acquisition of, and merger
with, Alcon will be completed in the expected form or within the expected time
frame or at all. Nor can there be any guarantee that Novartis will be able to
realize any of the potential synergies, strategic benefits or opportunities as a
result of the proposed acquisition. In particular, management's expectations
could be affected by, among other things, whether or not a market develops for
the notes; whether or not we issue additional secured or unsecured debt in the
future; whether we decide to redeem the notes; unexpected clinical trial
results, including additional analysis of existing clinical data or unexpected
new clinical data; unexpected regulatory actions or delays or government
regulation generally; the Novartis Group's ability to obtain or maintain patent
or other proprietary intellectual property protection; uncertainties regarding
actual or potential legal proceedings, including, among others, product
liability litigation, litigation regarding sales and marketing practices,
government investigations and intellectual property disputes; competition in
general; government, industry, and general public pricing and other political
pressures; uncertainties regarding the after-effects of the recent global
financial and economic crisis; uncertainties regarding future global exchange
rates and uncertainties regarding future demand for Novartis products;
uncertainties involved in the development of new pharmaceutical products; the
impact that the foregoing factors could have on the values attributed to the
Novartis Group's assets and liabilities as recorded in the Novartis Group's
consolidated balance sheet; and other risks and factors referred to in the
Prospectus and Prospectus Supplement for the notes, and in Novartis AG's current
Form 20-F on file with the U.S. Securities and Exchange Commission. Should one
or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated or expected. Novartis is
providing the information in these materials as of this date and does not
undertake any obligation to update any forward-looking statements as a result of
new information, future events or otherwise.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff(at)novartis.com
e-mail: media.relations(at)novartis.com
Novartis Investor Relations
Central phone: +41 61 324 7944
Ruth Metzler-Arnold +41 61 324 9980 North America:
Pierre-Michel Bringer +41 61 324 1065 Richard Jarvis +1 212 830 2433
John Gilardi +41 61 324 3018 Jill Pozarek +1 212 830 2445
Thomas Hungerbuehler +41 61 324 8425 Edwin Valeriano +1 212 830 2456
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-mail:
[HUG#1392318]
--- End of Message ---
Novartis International AG
Postfach Basel null
WKN: 904278;ISIN: CH0012005267;
Media release (PDF): http://hugin.info/134323/R/1392318/349931.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.03.2010 - 01:15 Uhr
Sprache: Deutsch
News-ID 1011125
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Basel
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 210 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis announces USD 5 billion bond issue
"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
